<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Middle East J Dig Dis</journal-id><journal-id journal-id-type="iso-abbrev">Middle East J Dig Dis</journal-id><journal-id journal-id-type="publisher-id">Middle East J Dig Dis</journal-id><journal-id journal-id-type="publisher-id">MEJDD</journal-id><journal-title-group><journal-title>Middle East Journal of Digestive Diseases</journal-title></journal-title-group><issn pub-type="ppub">2008-5230</issn><issn pub-type="epub">2008-5249</issn><issn-l>2008-5230</issn-l><publisher><publisher-name>Iranian Association of Gastroerterology and Hepatology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26106468</article-id><article-id pub-id-type="pmc">4430797</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Clarithromycin vs. Gemifloxacin in Quadruple Therapy Regimens for Empiric Primary Treatment of <italic>Helicobacter pylori</italic> Infection: A Randomized Clinical Trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Masoodi</surname><given-names>Mohsen</given-names></name><xref ref-type="aff" rid="A01">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Talebi-Taher</surname><given-names>Mahshid</given-names></name><xref ref-type="aff" rid="A02">
<sup>2</sup>
</xref><xref rid="COR1" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Tabatabaie</surname><given-names>Khadijeh</given-names></name><xref ref-type="aff" rid="A03">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Khaleghi</surname><given-names>Siamak</given-names></name><xref ref-type="aff" rid="A04">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Faghihi</surname><given-names>Amir-Hossein</given-names></name><xref ref-type="aff" rid="A01">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Agah</surname><given-names>Shahram</given-names></name><xref ref-type="aff" rid="A01">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Asadi</surname><given-names>Reyhaneh</given-names></name><xref ref-type="aff" rid="A03">
<sup>3</sup>
</xref></contrib></contrib-group><aff id="A01"><sup>1</sup> Associate professor, Colorectal Research Center, Rasoul-e-Akram General Hospital, Iran University of Medical Sciences, Tehran, Iran
</aff><aff id="A02"><sup>2</sup> Associate professor, Antimicrobial Resistance Research Center, Infectious Diseases Department, Rasoul-e-Akram General Hospital, Iran University of Medical Sciences, Tehran, Iran
</aff><aff id="A03"><sup>3</sup> Researcher, Rasoul-e-Akram General Hospital, Iran University of Medical Sciences, Tehran, Iran
</aff><aff id="A04"><sup>4</sup> Assistant professor, Colorectal Research Center, Rasoul-e-Akram General Hospital, Iran University of Medical Sciences, Tehran, Iran
</aff><author-notes><corresp id="COR1"><label>*</label><bold> Corresponding Author:</bold> Mahshid Talebi-Taher, MD, MPH Sattarkhan St., Niayesh, Rasoul-e-Akram General Hospital, Tehran, Iran Tel: + 98 21 66507056 Fax: +98 21 66506864 <email>mtalebitaher2000@yahoo.com</email></corresp></author-notes><pub-date pub-type="ppub"><month>4</month><year>2015</year></pub-date><volume>7</volume><issue>2</issue><fpage>88</fpage><lpage>93</lpage><history><date date-type="received"><day>28</day><month>12</month><year>2014</year></date><date date-type="accepted"><day>10</day><month>3</month><year>2015</year></date></history><permissions><copyright-statement>&#x000a9; 2015 by Middle East Journal of Digestive Diseases</copyright-statement><copyright-year>2015</copyright-year><license><license-p>
This work is published by Middle East Journal of Digestive Diseases as an open access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-sa/4.0/">http://creativecommons.org/licenses/by-nc-sa/4.0/</ext-link>). Non-commercial uses of the work are permitted, provided the original work is properly cited.
</license-p></license></permissions><self-uri xlink:href="http://mejdd.org">http://mejdd.org</self-uri><abstract><p> BACKGROUND</p><p>
Eradication of <italic>Helicobacter pylori</italic> infection plays a crucial role in the treatment of peptic ulcer. Clarithromycin resistance is a major cause of treatment failure. This randomized clinical trial aimed at evaluating the efficacy of a clarithromycin versus gemifloxacin containing quadruple therapy regimen in eradication of <italic>H.pylori</italic> infection.
</p><p>METHODS</p><p>
In this randomized double blind clinical trial (RCT 2012102011054N2), a total of 120 patients were randomized to two groups of 60 patients each. Patients with proven <italic>H.pylori</italic> infection were consecutively assigned into two groups to receive OBAG or OBAC in gastroenterology clinic in Rasoul-e- Akram General Hospital in Tehran, Iran. The patients in the OBAG group received omeprazole (20 mg) twice daily, bismuth subcitrate (240 mg) twice daily, amoxicillin (1 gr) twice daily, and gemifloxacin (320 mg) once daily, and those in the OBAC group received omeprazole (20 mg) twice daily, 240 mg of bismuth subcitrate twice daily, amoxicillin (1 gr) twice daily, and clarithromycin (500 mg) twice daily for 10 days.
</p><p>
RESULTS
</p><p>
Five patients from each group were excluded from the study because of poor compliance, so 110 patients completed the study. The intention-to-treat eradication rate was 61.6% and 66.6% for the OBAC and OBAG groups, respectively. According to the per protocol analysis, the success rates of eradication of <italic>H.pylori</italic> infection were 67.2% and 72.7% for OBAC and OBAG groups, respectively (<italic>p</italic>=0.568).
</p><p>
CONCLUSION
</p><p>The results of this study suggest that gemifloxacin containing regimen is at least as effective as clarithromycin regimen; hence, this new treatment could be considered as an alternative for the patients who cannot tolerate clarithromycin.</p></abstract><kwd-group><kwd><italic>H.pylori</italic></kwd><kwd>Gemifloxacin</kwd><kwd>Clarithromycin</kwd><kwd>Iran</kwd></kwd-group><counts><table-count count="3"/><ref-count count="27"/><page-count count="6"/></counts></article-meta><notes><p> Please cite this paper as:</p><p>Masoodi M, Talebi-Taher M, Tabatabaie K, Khaleghi S, Faghihi AH, Agah S, Asadi R. Clarithromycin vs. Gemifloxacin in Quadruple Therapy Regimens for Empiric Primary Treatment of Helicobacter pylori Infection: A Randomized Clinical Trial. Middle East J Dig Dis 2015;7:88-93.</p></notes></front><body><sec sec-type="introduction" id="s1"><title>INTRODUCTION</title><p>
<italic>Helicobacter pylori</italic> infection is not only a major cause of gastritis, peptic ulcer, gastric cancer, and MALT (mucosa-associated lymphoid tissue) lymphoma but also plays a leading role in creation of iron deficiency anemia, vitamin B12 deficiency, and idiopathic thrombocytopenic purpura.<sup><xref rid="R1" ref-type="bibr">1</xref></sup>
</p><p>
Eradication rates in the first-line <italic>H.pylori</italic> therapy have been declining over the years, essentially due to increasing resistance against the recommended antibiotics of metronidazole and clarithromycin. Resistance of <italic>H.pylori</italic> to clarithromycin is an important reason for the treatment failure.<sup><xref rid="R2" ref-type="bibr">2</xref>,<xref rid="R3" ref-type="bibr">3</xref></sup>
</p><p>
Fluoroquinolones are active against gram&#x02013;negative bacteria such as <italic>H.pylori</italic> and have a synergistic effect with proton pump inhibitors (PPIs).<sup><xref rid="R4" ref-type="bibr">4</xref>,<xref rid="R5" ref-type="bibr">5</xref></sup> Some data showed that levofloxacin-based therapy was an effective treatment with 70-80% eradication rate.<sup><xref rid="R6" ref-type="bibr">6</xref>,<xref rid="R7" ref-type="bibr">7</xref></sup> Minehart evaluated the susceptibility of <italic>H.pylori</italic> to fluoroquinolones, and found that gemifloxacin was the most active agent followed by gatifloxacin, ciprofloxacin, levofloxacin, and moxifloxacin.<sup><xref rid="R8" ref-type="bibr">8</xref></sup>
</p><p>
Some studies in Iran showed that the resistance rate to clarithromycin was in the range of 5% to 45.2%.<sup><xref rid="R9" ref-type="bibr">9</xref>,<xref rid="R10" ref-type="bibr">10</xref></sup> Shokrzadeh and colleagues reported the resistance rates to metronidazole, ciprofloxacin, clarithromycin, and tetracycline as 40.5%, 2.4%, 14.3%, and 4.8%, respectively.<sup><xref rid="R11" ref-type="bibr">11</xref></sup> This alarming finding indicates an urgent need for introduction of new antibiotics in Iran.
</p><p>
The present study aimed at evaluating the efficacy of a clarithromycin versus gemifloxacin containing quadruple therapy regimen in eradication of <italic>H.pylori</italic> infection.
</p></sec><sec sec-type="materials|methods" id="s2"><title>MATERIALS AND METHODS</title><p>
This double blind randomized clinical trial (RCT 2012102011054N2) was conducted in Rasoul-e-Akram Medical University Hospital (Tehran, Iran) during 2012-2013. The participants were chosen from those patients with the complaint of dyspepsia who referred to the Gastroenterology Clinic of the hospital. They were enrolled for this study after giving informed consent.
</p><p>
A total of 120 patients were included to make two groups of 60 patients. The sample size was calculated assuming eradication of <italic>H.pylori</italic> in at least 85% of treated patients, aiming to detect a difference of 10% based on a 0.80 power to detect significant difference (<italic>p</italic>=0.05).
</p><p>
Exclusion criteria were: receiving <italic>H.pylori</italic> treatment, pregnancy, age lower than 18 years, history of chronic renal failure, congestive heart failure, decompensated liver cirrhosis, and gastric surgery.
</p><p>
The presence of <italic>H.pylori</italic> was defined as positive <sup>
13
</sup>C-urea breath test (UBT), positive pathology and/or rapid urease test (RUT). All biopsy samples were stained with hematoxylin &#x00026; eosin and giemsa in Pathology Department by a pathologist, who was blinded to the treatment arm. The result of RUT was defined positive if the color of the gel turned pink or red 6 hours after examination. Of the 120 patients, 77 underwent endoscopy and were diagnosed by using RUT and/or histological evaluation (64.1%), and 43 were diagnosed by UBT (35.9%). Endoscopy was performed by the discretion of the managing physician.
</p><p>
A trained interviewer obtained demographic data and filled a standardized questionnaire. The participants were randomly assigned into two groups to receive OBAG or OBAC. The former group received omeprazole (20 mg) twice daily, bismuth subcitrate (240 mg) twice daily, amoxicillin (1 gr) twice daily, and gemifloxacin (320 mg) once daily for 10 days, and the latter group received omeprazole (20 mg) twice daily, bismuth subcitrate (240 mg) twice daily, amoxicillin (1 gr) twice daily, and clarithromycin (500 mg) twice daily for 10 days.
</p><p>
The participants were requested to refer again to the clinic during the second week to evaluate their compliance, as well as adverse drug effects. Compliance was acceptable when over 80% of the total medications were taken. The adverse effects included anorexia, nausea, vomiting, headache, skin rash, and bitter mouth. All the participants underwent UBT 8 weeks after completion of treatment to confirm <italic>H.pylori</italic> eradication.
</p><p>
Gender distribution as well as the efficacy and frequency of side effects in the two groups were compared by Chi-square test. Data analysis was performed on both per protocol (PP) and intention-to-treat (ITT) bases. A <italic>p</italic>-value&#x0003c;0.05 was considered as statistically significant. Statistical analyses were performed using the SPSS software (version18; SPSS Inc.).
</p><p>
This study was approved by both the Deputy Research of Iran University of Medical Sciences and Colorectal Research Center at Rasoul-e-Akram General Hospital, Tehran, Iran.
</p></sec><sec sec-type="results" id="s3"><title>RESULTS</title><p>
A total of 120 patients were enrolled in the study, and randomly assigned into OBAG (n=60) or OBAC (n=60) groups. Five patients from each group were excluded from the study because of poor compliance. Both groups had similar compliance according to the number of pills used (OBAG=98.3%, OBAC=97.1%, <italic>p</italic>=0.903).
</p><p>
Finally, 110 patients completed their treatment and follow-up. They had a mean age of 40.57&#x000b1;12.74 years (range, 19-81 years). Fifty four (49.09%) patients were men. ITT and PP analyses showed similar eradication rate in both groups. According to the PP analysis, the success rates of eradication of <italic>H.pylori</italic> infection were 67.2% and 72.7% for OBAC and OBAG groups, respectively (<italic>p</italic>=0.568, <xref ref-type="table" rid="T1">table 1</xref>).
</p><table-wrap id="T1" orientation="portrait" position="float"><label>
Table 1
</label><caption><title>
Demographic data and treatment results in patients receiving OBAC and/or OBAG
</title></caption><table frame="hsides" rules="none"><tbody><tr style="border-width: 1px 0px 1pt 0px ; border-style:solid none solid none;border-color:#00adee"><td rowspan="1" colspan="1">
<bold>Variables </bold>
</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">
<bold>Gemifloxacin</bold>
</td><td rowspan="1" colspan="1">
<bold>Clarithromycin</bold>
</td><td rowspan="1" colspan="1">
<italic>p</italic>
<bold>-value</bold>
</td></tr><tr style="border-width: 0px 0px 1pt 0px ; border-style:none none solid none;border-color:#00adee"><td rowspan="1" colspan="1">Mean age</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"> 41.20&#x000b1;14.00</td><td rowspan="1" colspan="1">39.93&#x000b1;11.98</td><td rowspan="1" colspan="1">0.646</td></tr><tr style="border-width: 0px 0px 1pt 0px ; border-style:none none solid none;border-color:#00adee"><td rowspan="1" colspan="1">Male</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">22 (40%)</td><td rowspan="1" colspan="1">34 (58.3%)</td><td rowspan="1" colspan="1">0.028</td></tr><tr style="border-width: 0px 0px 1pt 0px ; border-style:none none solid none;border-color:#00adee"><td rowspan="1" colspan="1">Smoking</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">6 (13.3%)</td><td rowspan="1" colspan="1">6 (13.3%) </td><td rowspan="1" colspan="1">0.990</td></tr><tr style="border-width: 0px 0px 1pt 0px ; border-style:none none solid none;border-color:#00adee"><td rowspan="1" colspan="1">Endoscopy</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">38(69.09%) </td><td rowspan="1" colspan="1">39(70.90%)</td><td rowspan="1" colspan="1">0.890</td></tr><tr style="border-width: 0px 0px 1pt 0px ; border-style:none none solid none;border-color:#00adee"><td rowspan="3" colspan="1">Endoscopy</td><td rowspan="1" colspan="1">Non-erosive gastritis</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">2</td><td rowspan="3" colspan="1">0.870</td></tr><tr style="border-width: 0px 0px 1pt 0px ; border-style:none none solid none;border-color:#00adee"><td rowspan="1" colspan="1"> Erosive gastritis</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">14</td></tr><tr style="border-width: 0px 0px 1pt 0px ; border-style:none none solid none;border-color:#00adee"><td rowspan="1" colspan="1">Peptic ulcer</td><td rowspan="1" colspan="1">21</td><td rowspan="1" colspan="1">23</td></tr><tr style="border-width: 0px 0px 1pt 0px ; border-style:none none solid none;border-color:#00adee"><td rowspan="2" colspan="1">Treatment result</td><td rowspan="1" colspan="1">
ITT<sup>1</sup>(n=60)
</td><td rowspan="1" colspan="1"> 40 (66.6%)</td><td rowspan="1" colspan="1"> 37 (61.6%)</td><td rowspan="2" colspan="1">0.568</td></tr><tr style="border-width: 0px 0px 1pt 0px ; border-style:none none solid none;border-color:#00adee"><td rowspan="1" colspan="1">
PP<sup>2</sup>(n=55)
</td><td rowspan="1" colspan="1"> 40 (72.7%) </td><td rowspan="1" colspan="1">37 (67.2%)</td></tr></tbody></table><table-wrap-foot><fn><p>
<sup>
1
</sup>ITT= intention to treat,
</p><p>
<sup>
2
</sup>PP=per protocol
</p></fn></table-wrap-foot></table-wrap><p>
There was significant statistical difference in the eradication rate of <italic>H.pylori</italic> infection according to the pathological findings between the two groups (<italic>p</italic>=0.001, <xref ref-type="table" rid="T2">table 2</xref>). In logistic regression analysis, after adjusting for endoscopic and pathological findings, there was no significant difference between the two groups in response to the treatment (<italic>p</italic>=0.732).
</p><table-wrap id="T2" orientation="portrait" position="float"><label>
Table 2
</label><caption><title>
Eradication rate of <italic>H. pylori</italic> infection in the two groups receiving OBAC and/or OBAG tratment
</title></caption><table frame="hsides" rules="none"><tbody><tr style="border-width: 1px 0px 1pt 0px ; border-style:solid none solid none;border-color:#00adee"><td rowspan="1" colspan="1">
<bold>Endoscopic findings OBAC group</bold>
</td><td rowspan="1" colspan="1">
<bold>n</bold>
</td><td rowspan="1" colspan="1">
<bold> Eradication rate(%)</bold>
</td><td rowspan="1" colspan="1">
<italic>p</italic>
<bold>-value</bold>
</td></tr><tr><td rowspan="1" colspan="1">
PUD<sup>1</sup>
</td><td rowspan="1" colspan="1">23</td><td rowspan="1" colspan="1">16 (73.91)</td><td rowspan="1" colspan="1">0.001</td></tr><tr><td rowspan="1" colspan="1">Erosive gastritis</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">8 (57.14)</td><td rowspan="1" colspan="1">
</td></tr><tr><td rowspan="1" colspan="1">Non-erosive gastritis </td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">2 (100)</td><td rowspan="1" colspan="1">
</td></tr><tr><td rowspan="1" colspan="1">
<bold>Endoscopic findings OBAG group</bold>
</td><td rowspan="1" colspan="1">
</td><td rowspan="1" colspan="1">
</td><td rowspan="1" colspan="1">
</td></tr><tr><td rowspan="1" colspan="1">
PUD<sup>1</sup>
</td><td rowspan="1" colspan="1">21</td><td rowspan="1" colspan="1"> 11 (52.38)</td><td rowspan="1" colspan="1">
</td></tr><tr><td rowspan="1" colspan="1">Erosive gastritis</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">10 (71.42)</td><td rowspan="1" colspan="1">
</td></tr><tr style="border-width: 0px 0px 1pt 0px ; border-style:none none solid none;border-color:#00adee"><td rowspan="1" colspan="1">Non-erosive gastritis</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1"> 1 (33.33)</td><td rowspan="1" colspan="1">
</td></tr></tbody></table><table-wrap-foot><fn><p>
<sup>
1
</sup>Peptic ulcer disease
</p></fn></table-wrap-foot></table-wrap><p>
Adverse drug effects were reported in 37 (61.66%) and 19 (31.66%) patients in the clarithromycin and gemifloxacin groups, respectively. Among those, only bitter mouth was significantly more common in the clarithromycin group (<italic>p</italic>=0.001, <xref ref-type="table" rid="T3">table 3</xref>).
</p><table-wrap id="T3" orientation="portrait" position="float"><label>
Table 3
</label><caption><title>
Adverse effects reported by the patients during the treatment
</title></caption><table frame="hsides" rules="none"><tbody><tr style="border-width: 1px 0px 1pt 0px ; border-style:solid none solid none;border-color:#00adee"><td rowspan="1" colspan="1">
<bold>Adverse effect</bold>
</td><td rowspan="1" colspan="1">
<bold>OBAC (n=55)</bold>
</td><td rowspan="1" colspan="1">
<bold>OBAG (n=55)</bold>
</td></tr><tr><td rowspan="1" colspan="1">Nausea</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">2</td></tr><tr><td rowspan="1" colspan="1">Vomiting</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1">Diarrhea</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">3</td></tr><tr><td rowspan="1" colspan="1">Abdominal pain</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">3</td></tr><tr><td rowspan="1" colspan="1">Headache</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">2</td></tr><tr><td rowspan="1" colspan="1">Skin rash</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">6</td></tr><tr style="border-width: 0px 0px 1pt 0px ; border-style:none none solid none;border-color:#00adee"><td rowspan="1" colspan="1">
Bitter mouth<sup>*</sup>
</td><td rowspan="1" colspan="1">25</td><td rowspan="1" colspan="1">2</td></tr></tbody></table><table-wrap-foot><fn><p>
<sup>*</sup>
<italic>p</italic>&#x0003c;0.001
</p></fn></table-wrap-foot></table-wrap></sec><sec sec-type="discussion" id="s4"><title>DISCUSSION</title><p>
Our findings in the present study showed that gemifloxacin is as effective as clarithromycin in eradication of <italic>H.pylori</italic> infection. 5-45% of <italic>H.pylori</italic> isolates from Iran show some degrees of resistance to clarithromycin.<sup><xref rid="R9" ref-type="bibr">9</xref>,<xref rid="R10" ref-type="bibr">10</xref></sup> To tackle this problem, an alternative drug that is effective, safe, and easy to use has been searched.
</p><p>
The eradication rate has got a decreasing trend by using clarithromycin from 2000 to 2012 in Iran. Fakheri and colleagues showed that the ITT eradication rate was 85% for clarithromycin in quadruple therapy regimens in 2000.<sup><xref rid="R12" ref-type="bibr">12</xref></sup> However, similar to the present study, Minakari and co-workers found the eradication rates of ITT and PP as 64.5% and 74.7%, respectively, by using amoxicillin, clarithromycin, bismuth and omeprazole as the second-line therapy.<sup><xref rid="R13" ref-type="bibr">13</xref></sup>
</p><p>
The main risk factor for clarithromycin resistance is previous consumption of macrolides. Although clarithromycin had not been introduced in Iran, some studies has shown 17% resistance rate to this drug. Erythromycin was used instead of it in Iran.<sup><xref rid="R14" ref-type="bibr">14</xref>,<xref rid="R15" ref-type="bibr">15</xref></sup>
</p><p>
Several authors have reported an increasing trend in clarithromycin resistance rates in other areas of the world such as Latin America and Turkey.<sup><xref rid="R16" ref-type="bibr">16</xref>,<xref rid="R17" ref-type="bibr">17</xref></sup> In contrast, there was no change in the trend of <italic>H.pylori</italic> eradication rate by using PPI, clarithromycin and amoxicillin over the recent 11 years in Korea.<sup><xref rid="R18" ref-type="bibr">18</xref></sup>
</p><p>
Unfortunately, inappropriate use of antibiotics, especially macrolides in Iran has led to the emergence and spread of resistant bacteria, and plans to reduce the over-prescription of antibiotics by physicians should be arranged.
</p><p>
It is important to keep in mind that clarithromycin containing triple therapy is not an appropriate regimen when resistance is between 7% and 10%.<sup><xref rid="R19" ref-type="bibr">19</xref></sup> So identifying alternative treatments that are more effective than clarithromycin against <italic>H.pylori</italic> is crucial.
</p><p>
Some randomized trials have shown that a levofloxacin containing therapy is more effective compared with a clarithromycin containing regimen.<sup><xref rid="R6" ref-type="bibr">6</xref>,<xref rid="R20" ref-type="bibr">20</xref></sup> There are reports showing that levofloxacin had significant activity against <italic>H.pylori</italic> in vitro but no cross-resistance to B-lactams and macrolides. Moreover, it had a synergistic effect with PPIs.<sup><xref rid="R4" ref-type="bibr">4</xref>-<xref rid="R5" ref-type="bibr">5</xref></sup>
</p><p>
The eradication rate of levofloxacin-containing triple therapy ranged from 72% to 96%. Some authors suggest that this regimen is reasonable in populations with clarithromycin resistance greater than 15-20% and fluoroquinolones resistance less than 10%.<sup><xref rid="R21" ref-type="bibr">21</xref></sup> But it might not be as the first-line therapy because over-consumption of fluoroquinolones would likely lead to the emergence of more quinolone-resistant pathogens responsible for other organs infections.<sup><xref rid="R19" ref-type="bibr">19</xref></sup>
</p><p>
A first-line eradication regimen should be based on the prevalence of antimicrobial resistance in Iran. Primary resistance of <italic>H.pylori</italic> isolates in Iran was to clarithromycin (34%), levofloxacin (5.3%), and moxifloxacin (4.6%).<sup><xref rid="R22" ref-type="bibr">22</xref></sup> So we need more studies to identify the best regimen for <italic>H.pylori</italic> infection therapy.
</p><p>
Gemifloxacin has shown an spectrum of activity against Gram-positive and Gram-negative bacteria. Its mechanism of action focuses on inhibiting DNA gyrase and topoisomerase, thus preventing cellular replication.<sup><xref rid="R23" ref-type="bibr">23</xref></sup> Some studies have shown that gemifloxacin is superior to levofloxacin in antimicrobial activity against <italic>H. pylori</italic>, and even overcomes some levofloxacin resistance.<sup><xref rid="R8" ref-type="bibr">8</xref>,<xref rid="R24" ref-type="bibr">24</xref></sup>
</p><p>
Graham suggested that in empiric therapies that did not reliably yield 90% or greater cure, ITT should not be prescribed.<sup><xref rid="R25" ref-type="bibr">25</xref></sup> It has been reported that standard triple therapy is not a suitable regimen in the areas with clarithromycin resistance over 20% because the PP eradication rate of that regimen is often less than 85%, and the ITT eradication rate is usually less than 80%.<sup><xref rid="R26" ref-type="bibr">26</xref></sup>
</p><p>
To overcome the problem of the growing clarithromycin resistance in the Middle East, several methods of treatment have been proposed, including the extension of the treatment duration to 14 days, and using bismuth-containing quadruple, sequential, and concomitant treatments.<sup><xref rid="R19" ref-type="bibr">19</xref></sup> Nasa and colleagues reported that sequential therapy was better than standard therapy for eradicating <italic>H.pylori</italic> infection.<sup><xref rid="R27" ref-type="bibr">27</xref></sup> More studies are needed to find the best regimen for eradication of <italic>H.pylori</italic> in Iran.
</p><p>
The results of this study suggest that gemifloxacin containing regimen is at least as effective as clarithromycin regimen; hence, this new treatment could be considered as an alternative choice for the patients who cannot tolerate clarithromycin. Non-optimal result of the two regimens may be due to the emergence of resistant strains of <italic>H.pylori</italic> in Iran. So empirical use of these regimens without susceptibility testing may not be appropriate.
</p></sec><sec id="s5"><title>ACKNOWLEDGMENT</title><p>
This study was supported by a grant from the Research Council of Iran University of Medical Sciences, and Colorectal Research Center at Rasoul-e-Akram Hospital (grant No. 18790). We would like to thank the staff in the Division of Gastroenterology at Rasoul-e-Akram General Teaching Hospital, Tehran, Iran.
</p></sec><sec id="s6"><title>CONFLICT OF INTEREST</title><p>
The authors declare no conflict of interest related to this work.
</p></sec></body><back><ref-list><title>References</title><ref id="R1"><label>1</label><element-citation publication-type="journal"><name><surname>Franceschi</surname><given-names>F</given-names></name><name><surname>Zuccala</surname><given-names>G</given-names></name><name><surname>Roccarina</surname><given-names>D</given-names></name><name><surname>Gasbarrini</surname><given-names>A</given-names></name><article-title>Clinical effects of Helicobacter pylori outside the stomach</article-title><source>Nat Rev Gastroenterol Hepatol</source><year>2014</year><volume>11</volume><fpage>234</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">24345888</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><name><surname>Krasz</surname><given-names>S</given-names></name><name><surname>Miehlke</surname><given-names>S</given-names></name><name><surname>Berning</surname><given-names>M</given-names></name><name><surname>Morgner</surname><given-names>A</given-names></name><name><surname>Labenz</surname><given-names>J</given-names></name><article-title>[Current value of quinolones in Helicobacter pylori therapy]</article-title><source>Z Gastroenterol</source><year>2011</year><volume>49</volume><fpage>989</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">21811951</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><name><surname>Ducons</surname><given-names>JA</given-names></name><name><surname>Santolaria</surname><given-names>S</given-names></name><name><surname>Guirao</surname><given-names>R</given-names></name><name><surname>Ferrero</surname><given-names>M</given-names></name><name><surname>Montoro</surname><given-names>M</given-names></name><name><surname>Gomollon</surname><given-names>F</given-names></name><article-title>Impact of clarithromycin resistance on the effectiveness of a regimen for Helicobacter pylori: A prospective study of 1-week lansoprazole, amoxycillin and clarithromycin in active peptic ulcer</article-title><source>Aliment Pharmacol Ther</source><year>1999</year><volume>13</volume><fpage>775</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">10383507</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><name><surname>Sanchez</surname><given-names>JE</given-names></name><name><surname>Saenz</surname><given-names>NG</given-names></name><name><surname>Rincon</surname><given-names>MR</given-names></name><name><surname>Martin</surname><given-names>IT</given-names></name><name><surname>Sanchez</surname><given-names>EG</given-names></name><name><surname>Martinez</surname><given-names>MJ</given-names></name><article-title>Susceptibility of Helicobacter pylori to mupirocin, oxazolidones, quinupristin/dalfopristin and new quinolones</article-title><source>J Antimicrob Chemother</source><year>2000</year><volume>46</volume><fpage>283</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">10933654</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><name><surname>Tanaka</surname><given-names>M</given-names></name><name><surname>Isogai</surname><given-names>E</given-names></name><name><surname>Isogai</surname><given-names>H</given-names></name><name><surname>Hayashi</surname><given-names>S</given-names></name><name><surname>Sugiyama</surname><given-names>T</given-names></name><name><surname>Sato</surname><given-names>K</given-names></name><article-title>Synergic effect of quinolone antibacterial agents and proton pump inhibitors on Helicobacter pylori</article-title><source>J Antimicrob Chemother</source><year>2002</year><volume>49</volume><fpage>1039</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">12039901</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><name><surname>Kuo</surname><given-names>CH</given-names></name><name><surname>Hu</surname><given-names>HM</given-names></name><name><surname>Kuo</surname><given-names>FC</given-names></name><name><surname>Hsu</surname><given-names>PI</given-names></name><name><surname>Chen</surname><given-names>A</given-names></name><name><surname>Yu</surname><given-names>FJ</given-names></name><etal/><article-title>Efficacy of levofloxacin-based rescue therapy for Helicobacter pylori infection after standard triple therapy: A randomized control trial</article-title><source>J Antimicrob Chemother</source><year>2009</year><volume>63</volume><fpage>1017</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">19246508</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><name><surname>Gisbert</surname><given-names>JP</given-names></name><name><surname>Fernandez-Bermejo</surname><given-names>M</given-names></name><name><surname>Molina-Infante</surname><given-names>J</given-names></name><name><surname>Perez-Gallardo</surname><given-names>B</given-names></name><name><surname>Prieto-Bermejo</surname><given-names>AB</given-names></name><name><surname>Mateos-Roodriguez</surname><given-names>JM</given-names></name><etal/><article-title>First-line triple therapy with levofloxacin for Helicobacter pylori eradication</article-title><source>Aliment Pharmacol Therapy</source><year>2007</year><volume>26</volume><fpage>495</fpage><lpage>500</lpage></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><name><surname>Minehart</surname><given-names>HW</given-names></name><name><surname>Chalker</surname><given-names>AF</given-names></name><article-title>In vitro activity of gemifloxacin against Helicobacter pylori</article-title><source>J Antimicrob Chemother</source><year>2001</year><volume>47</volume><fpage>360</fpage><lpage>1</lpage><pub-id pub-id-type="pmid">11222574</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><name><surname>Farshad</surname><given-names>S</given-names></name><name><surname>Alborzi</surname><given-names>A</given-names></name><name><surname>Japoni</surname><given-names>A</given-names></name><name><surname>Ranjbar</surname><given-names>R</given-names></name><name><surname>Hosseini ASI</surname><given-names>K</given-names></name><name><surname>Badiee</surname><given-names>P</given-names></name><etal/><article-title>Antimicrobial susceptibility of Helicobacter pylori strains isolated from patients in Shiraz, Southern Iran</article-title><source>World J Gastroenterol</source><year>2010</year><volume>16</volume><fpage>5746</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">21128326</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><name><surname>Abadi</surname><given-names>AT</given-names></name><name><surname>Taghavi</surname><given-names>T</given-names></name><name><surname>Mobarez</surname><given-names>AM</given-names></name><name><surname>Carpenter</surname><given-names>BM</given-names></name><article-title>Frequency of antibiotic resistance in Helicobacter pylori strains isolated from the northern population of Iran</article-title><source>J Microbio</source><year>2011</year><volume>49</volume><fpage>987</fpage><lpage>93</lpage></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><name><surname>Shokrzadeh</surname><given-names>L</given-names></name><name><surname>Jafari</surname><given-names>F</given-names></name><name><surname>Dabiri</surname><given-names>H</given-names></name><name><surname>Baghaei</surname><given-names>K</given-names></name><name><surname>Zojaii</surname><given-names>H</given-names></name><name><surname>Alizadeh</surname><given-names>AH</given-names></name><etal/><article-title>Antibiotic susceptibility profile of Helicobacter pylori isolated from the dyspepsia patients in Tehran, Iran</article-title><source>Saudi J Gastroentero</source><year>2011</year><volume>17</volume><fpage>261</fpage><lpage>4</lpage></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><name><surname>Fakher</surname><given-names>H</given-names></name><name><surname>Malekzadeh</surname><given-names>R</given-names></name><name><surname>Merat</surname><given-names>S</given-names></name><name><surname>Khatibian</surname><given-names>M</given-names></name><name><surname>Fazel</surname><given-names>A</given-names></name><name><surname>Alizadeh</surname><given-names>BZ</given-names></name><etal/><article-title>Clarithromycin vs furazolidone in quadruple therapy regimens for the treatment of Helicobacter pylori in a population with a high metronidazole resistance rate Aliment</article-title><source>Pharmacol Ther</source><year>2001</year><volume>15</volume><fpage>411</fpage><lpage>6</lpage></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><name><surname>Minakari</surname><given-names>M</given-names></name><name><surname>Davarpanah Jazi</surname><given-names>AH</given-names></name><name><surname>Shavakhi</surname><given-names>A</given-names></name><name><surname>Moghareabed</surname><given-names>N</given-names></name><name><surname>Fatahi</surname><given-names>F</given-names></name><article-title>A randomized controlled trial: Efficacy and safety of azithromycin, ofloxacin, bismuth, and omeprazole compared with amoxicillin, clarithromycin, bismuth, and omeprazole as second-line therapy in patients with Helicobacter pylori infection</article-title><source>Helicobacter</source><year>2010</year><volume>15</volume><fpage>154</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">20402818</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><name><surname>Mohammadi</surname><given-names>M</given-names></name><name><surname>Doroud</surname><given-names>D</given-names></name><name><surname>Massarrat</surname><given-names>S</given-names></name><name><surname>Farahvash</surname><given-names>MJ</given-names></name><article-title>Clarithromycin resistance in Iranian Hpylori strains before introduction of clarithromycin</article-title><source>Helicobacter</source><year>2003</year><volume>8</volume><fpage>80</fpage><pub-id pub-id-type="pmid">12603622</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><name><surname>Cabrita</surname><given-names>J</given-names></name><name><surname>Oleastro</surname><given-names>M</given-names></name><name><surname>Matos</surname><given-names>R</given-names></name><name><surname>Manherte</surname><given-names>A</given-names></name><name><surname>Cabral</surname><given-names>J</given-names></name><name><surname>Barros</surname><given-names>R</given-names></name><etal/><article-title>Features and trends in Helicobacter pylori antibiotic resistance in Lisbon area, Portugal (1990-1999)</article-title><source>J Antimicrob Chemother</source><year>2000</year><volume>46</volume><fpage>1029</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">11102427</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><name><surname>Camargo</surname><given-names>MC</given-names></name><name><surname>Garcia</surname><given-names>A</given-names></name><name><surname>Riquelma</surname><given-names>A</given-names></name><name><surname>Otero</surname><given-names>W</given-names></name><name><surname>Camargo</surname><given-names>CA</given-names></name><name><surname>Hernandez-Garcia</surname><given-names>T</given-names></name><etal/><article-title>The problem of Helicobacter pylori resistance to antibiotics: A systematic review in Latin America</article-title><source>Am J Gastroenterol</source><year>2014</year><volume>109</volume><fpage>485</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">24589670</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><name><surname>Simsek</surname><given-names>H</given-names></name><name><surname>Blaban</surname><given-names>YH</given-names></name><name><surname>Gunes</surname><given-names>DD</given-names></name><name><surname>Hascelik</surname><given-names>G</given-names></name><name><surname>Ozarlan</surname><given-names>E</given-names></name><name><surname>Tatar</surname><given-names>G</given-names></name><article-title>Alarming clarithromycin resistance of Helicobacter pylori in Turkish population</article-title><source>Helicobacter</source><year>2005</year><volume>10</volume><fpage>360</fpage><lpage>1</lpage><pub-id pub-id-type="pmid">16104953</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><name><surname>Yoon</surname><given-names>JH</given-names></name><name><surname>Baik</surname><given-names>GH</given-names></name><name><surname>Sohn</surname><given-names>KM</given-names></name><name><surname>Kim</surname><given-names>DY</given-names></name><name><surname>Kim</surname><given-names>YS</given-names></name><name><surname>Suk</surname><given-names>KT</given-names></name><etal/><article-title>Trends in the eradication rates of Helicobacter pylori infection for eleven years</article-title><source>World J Gastroenterol</source><year>2012</year><volume>18</volume><fpage>6628</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">23236238</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><name><surname>Federico</surname><given-names>A</given-names></name><name><surname>Gravina</surname><given-names>AG</given-names></name><name><surname>Miranda</surname><given-names>A</given-names></name><name><surname>Loguercio</surname><given-names>C</given-names></name><name><surname>Romano</surname><given-names>M</given-names></name><article-title>Eradication of Helicobacter pylori infection: Which regimen first?</article-title><source>World J Gastroenterol</source><year>2014</year><volume>20</volume><fpage>665</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">24574740</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><name><surname>Romano</surname><given-names>M</given-names></name><name><surname>Cuomo</surname><given-names>A</given-names></name><name><surname>Gravina</surname><given-names>AG</given-names></name><name><surname>Miranda</surname><given-names>A</given-names></name><name><surname>Iovene</surname><given-names>MR</given-names></name><name><surname>Tlso</surname><given-names>A</given-names></name><etal/><article-title>Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomized trial</article-title><source>Gut</source><year>2010</year><volume>59</volume><fpage>1465</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">20947881</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><name><surname>Berning</surname><given-names>M</given-names></name><name><surname>Krasz</surname><given-names>S</given-names></name><name><surname>Miehlke</surname><given-names>S</given-names></name><article-title>Should quinolones come first in Helicobacter pylori therapy?</article-title><source>Therap Adv Gastroenterol</source><year>2011</year><volume>4</volume><fpage>103</fpage><lpage>14</lpage></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><name><surname>Talebi Bezmin Abadi</surname><given-names>A</given-names></name><name><surname>Ghasemzadeh</surname><given-names>A</given-names></name><name><surname>Taghvaei</surname><given-names>T</given-names></name><name><surname>Mobarez</surname><given-names>AM</given-names></name><article-title>Primary resistance of Helicobacter pylori to levofloxacin and moxifloxacin in Iran Intern</article-title><source>Emerg Med</source><year>2012</year><volume>7</volume><fpage>447</fpage><lpage>52</lpage></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><name><surname>Le</surname><given-names>TP</given-names></name><name><surname>Xiang</surname><given-names>YQ</given-names></name><article-title>Gemifloxacin</article-title><source>Drugs Todays(Barc)</source><year>2001</year><volume>37</volume><fpage>401</fpage><lpage>10</lpage></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><name><surname>Chang</surname><given-names>WL</given-names></name><name><surname>Kao</surname><given-names>CY</given-names></name><name><surname>Wu</surname><given-names>CT</given-names></name><name><surname>Huang</surname><given-names>AH</given-names></name><name><surname>Wu</surname><given-names>JJ</given-names></name><name><surname>Yang</surname><given-names>HB</given-names></name><etal/><article-title>Gemifloxacin can partially overcome Quinolone resistance of Hpylori with gyrA mutation in Taiwan</article-title><source>Helicobacter</source><year>2012</year><volume>17</volume><fpage>210</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">22515359</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><name><surname>Graham</surname><given-names>DY</given-names></name><name><surname>Shiotani</surname><given-names>A</given-names></name><article-title>New concepts of resistance in the treatment of Helicobacter pylori infections</article-title><source>Nat Clin Pract Gastroenterol Hepatol</source><year>2008</year><volume>5</volume><fpage>321</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">18446147</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><name><surname>Megraud</surname><given-names>F</given-names></name><article-title>Hpylori antibiotic resistance prevalence, importance, and advances in testing</article-title><source>Gut</source><year>2004</year><volume>53</volume><fpage>1374</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">15306603</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><name><surname>Nasa</surname><given-names>M</given-names></name><name><surname>Choksey</surname><given-names>A</given-names></name><name><surname>Phadke</surname><given-names>A</given-names></name><name><surname>Sawant</surname><given-names>P</given-names></name><article-title>Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: A randomized study</article-title><source>Indian J Gastroenterol</source><year>2013</year><volume>32</volume><fpage>392</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">24158898</pub-id></element-citation></ref></ref-list></back></article>